Key result
Bone marrow-derived cell therapy for chronic chagasic cardiomyopathy fails to translate from mice to humans.
Why the study?
Does bone marrow-derived cell therapy improve outcomes in chronic chagasic cardiomyopathy?
Does bone marrow-derived cell therapy improve outcomes in chronic chagasic cardiomyopathy?
This review highlights the challenges and reasons for failure in translating bone marrow-derived cell therapy for chronic chagasic cardiomyopathy from preclinical models to clinical applications.
Failed translation from mice to humans cautions against bone marrow cell therapy in chronic chagasic cardiomyopathy; leaves open need for better models.
Chagas disease is caused by a protozoan parasite Trypanosoma cruzi, which infects people through blood sucking insects. It is endemic in Latin America and the disease is being spread to developed countries as a result of the migration of infected individuals. In its chronic stage, Chagas disease can lead to a severe cardiomyopathy for which there is currently no cure. End-stage patients require heart transplantation, thus demanding new therapeutic modalities. Cell-based therapy has been proposed as an alternative for various forms of heart disease. Here we review the experimental evidence that led to the use of bone marrow-derived cells in putative therapy for chronic chagasic cardiomyopathy in animal models and in clinical trials, discussing the reasons for failure of the translation of results from mice to men.
No takes yet. Share an insight, caveat, or question.
Carvalho et al. (2012) conducted a review in Chronic chagasic cardiomyopathy. Bone marrow-derived cell therapy was evaluated. Bone marrow-derived cell therapy for chronic chagasic cardiomyopathy has been evaluated in animal models and clinical trials, but translation of results from mice to humans has failed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: